{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
beta carotene
to a specific field?
Status:
Investigational
Source:
INN:lefleuganan [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
INN:polvitolimod [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
Amdoxovir is a guanosine analogue nucleoside reverse transcriptase inhibitor that is active in vitro against both HIV-1 and HBV. It is deaminated intracellularly by adenosine deaminase to dioxolane guanine (DXG). DXG-triphosphate, the active form of the drug, has greater activity than DAPD-triphosphate. Amdoxovir is under development (phase II study) for the treatment of HIV infection. Five subjects demonstrated lens opacities during the study, although baseline evaluations were not performed. Clinical studies of amdoxovir are currently on hold pending additional safety data.
Status:
Investigational
Source:
INN:morphine glucuronide [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Morphine-6-glucuronide is a pharmacologically active metabolite of morphine that is being developed by CeNeS Pharmaceuticals as an alternative to morphine for the management of postoperative pain. Compared to morphine, Morphine-6-glucuronide has been reported to have6 and 86 times lower affinity for the human mu and kappa opioid receptors, respectively, and similar affinity for the delta opioid receptor. Morphine-6-glucuronide is was studied in phase III clinical trials for postoperative pain management. Unfortunately, Morphine-6-glucuronide failed to demonstrate superior safety compared to Morphine and further development was discontinued. Morphine-6-glucuronide accumulates after administration of morphine to patients with renal insufficiency, and analgesia can be obtained with lower doses of morphine compared to patients with normal renal function. More importantly, the dose should be reduced to avoid serious side-effects, although the simulations in this review did not account for side-effects.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Crolibulin is a tubulin-disrupting agent, interacting at the colchicine-binding site, developed by EpiCept Corporation (which was later acquired by Immune Pharmaceuticals). The compound exhibits anti-cancer effect by vascular disruption and inhibition of apoptosis. In preclinical animal tumor models, combination therapy with crolibulin has demonstrated the synergistic activity with cytotoxic drugs as well as anti-angiogenic drugs, such as Avastin. The drug was investigated in clinical trials for the treatment of anaplastic thyroid cancer and has demonstrated a positive effect.
Class (Stereo):
CHEMICAL (ABSOLUTE)
Cormethasone is a topical antiinflammatory corticosteroid discovered by Du Pont.
Status:
Investigational
Source:
INN:iometopane (¹²³I) [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Iometopane I-123 is a tropane derivative labeled with iodine-123 that was being developed by MGI GP (MGI Pharma) as an injectable Single-photon emission computed tomography (SPECT) imaging agent. The ability of iometopane to bind to the dopamine transporter on presynaptic dopaminergic nerve terminal in the striatum has been used to differentiate the uptake of the agent by the neurons in the striatum in patients with a Parkinsonian disorder from patients without a Parkinsonian disorder with high sensitivity and specificity. The diminished uptake of iometopane in the striatum on the SPECT images of patients with a Parkinsonian disorder can be applied to assess both disease trait and disease state (severity) reflected by the severity of the brain dopamine neuron loss. Unfortunately Phase III clinical trials and further development of iometopane was discontinued due to the inability to contract a suitable manufacturer for the clinical and commercial supply of iometopane on acceptable conditions in the US. Currently, Iometopane is mainly used in scientific research into the dopamine reuptake transporter.
Class (Stereo):
CHEMICAL (RACEMIC)
Prizidilol (also known as SKF 92657) is arylpyridazinylhydrazine derivative patented by Smith Kline and French Laboratories Ltd. as an antihypertensive agent. In clinical trials, Supine and standing blood pressure measured 24--27 h after drug intake was reduced Slight but significant decreases in heart rate were seen after moderate doses of prizidilol. A more pronounced blood pressure reduction was noticed 2--7 h after drug administration. Prizidilol was well tolerated, although dizziness and tiredness were reported by four patients and edema by two.
Status:
Investigational
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
PYM50018 (also known as Myogane or SARSAGENIN) has demonstrated neuroprotective effects in several preclinical models. It was observed that PYM50018 protects against neuronal damage, increases neurite outgrowth, reverses oxidative damage and reversed neuronal apoptosis. PYM50018 is in phase I clinical study for the treatment of amyotrophic lateral sclerosis (ALS).
